ArticleRSC advances2026
Spectrochemical, medicinal, and toxicological studies of moxifloxacin and its novel analogs: a quantum chemistry and drug discovery approach.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Density functional theory‑elucidated α-ZrP/phosphorus-nitrogen co-doped hollow carbon spheres composite for highly sensitive electrochemical detection of moxifloxacin.Mikrochimica acta · 2026Article
- Click chemistry of phenyl 1,2,3-triazole-2-pyridylpiperazine hybrids: synthesis, targeted anticancer activity, molecular modeling and computational studies.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moxifloxacin (MOX) is regarded as a fourth-generation fluoroquinolone, demonstrating effectiveness against multidrug-resistant tuberculosis (TB) by inhibiting bacterial DNA gyrase. The therapeutic effectiveness of MOX is negatively influenced by side effects that are dependent on dosage, including heart rate-corrected QT interval prolongation and hepatotoxicity. This study explored the physicochemical, spectral, biological, and pharmacokinetic properties of MOX and its analogues. We incorporated various functional groups such as CH
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.